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Abstract
T-cell receptors (TCRs) have emerged as a new class of therapeutics, most prominently for
cancer where they are the key components of new cellular therapies as well as soluble biologics.
Many studies have generated high affinity TCRs in order to enhance sensitivity. Recent
outcomes, however, have suggested that fine manipulation of TCR binding, with an emphasis on
specificity may be more valuable than large affinity increments. Structure-guided design is
ideally suited for this role, and here we studied the generality of structure-guided design as
applied to TCRs. We found that a previous approach, which successfully optimized the binding
of a therapeutic TCR, had poor accuracy when applied to a broader set of TCR interfaces. We
thus sought to develop a more general purpose TCR design framework. After assembling a large
dataset of experimental data spanning multiple interfaces, we trained a new scoring function that
accounted for unique features of each interface. Together with other improvements, such as
explicit inclusion of molecular flexibility, this permitted the design new affinity-enhancing
mutations in multiple TCRs, including those not used in training. Our approach also captured the
impacts of mutations and substitutions in the peptide/MHC ligand, and recapitulated recent
findings regarding TCR specificity, indicating utility in more general mutational scanning of
TCR–pMHC interfaces.
Keywords: affinity, mutational scanning, specificity, structure-guided design, T-cell receptor

Introduction
αβ T cells utilize clonotypic T-cell receptors (TCRs) to recognize antigens and initiate cellular
immune responses. TCRs have emerged as a new class of therapeutics, most prominently for the
treatment of cancer. Although in many ways similar to antibodies, TCRs differ in the complexity
of the receptor-ligand interface: whereas antibodies can be elicited to almost any antigen, TCRs
are restricted to linear peptide antigens presented by class I or class II MHC proteins (pMHC),
with the TCR invariably contacting both (Rossjohn et al., 2015). Additionally, TCRs do not
undergo affinity maturation, and, similar to naive antibodies, bind with weak-to-moderate
affinities and reduced specificity (Baker et al., 2012).
Recent advances have highlighted the potential therapeutic uses for TCRs with altered binding
properties. As T-cell potency can be improved with antigen affinity (Varela-Rohena et al., 2008;
Zhao et al., 2007), clinical trials with gene-modified T cells have explored the use of engineered,
high affinity TCRs for improved antigen targeting (Linette et al., 2013). High affinity TCRs are
also used as the antigen recognition component of soluble reagents designed to redirect naive,
unmodified T cells (Oates and Jakobsen, 2013).
Multiple methods have been used to generate high affinity TCRs, with the majority created using
yeast or phage display (Bowerman et al., 2009; Holler et al., 2000; Li et al., 2005; VarelaRohena et al., 2008; Zhao et al., 2007). However, recent findings have shown that careful control
is necessary when modifying TCRs. Due to their cross-reactive nature, enhancing affinity may

introduce new reactivities: improving affinity against one antigen can improve affinity towards
others, leading to reactivity towards antigens that might otherwise be ignored by T cells
expressing the wild-type receptor. This could include self-antigens, leading to possible off-target
recognition (Zhao et al., 2007). Such an outcome is believed to have led to fatal autoimmunity in
a recent clinical trial that used a high affinity TCR to target a melanoma antigen (Linette et al.,
2013). The likelihood of such an outcome may be increased if added ‘glue’ is directed more
towards the MHC protein than the peptide. Additionally, the relationship between TCR affinity
and potency is not well understood. Although some very high affinity TCRs show considerable
sensitivity (Varela-Rohena et al., 2008), in other cases improving affinity outside an optimal
window or above a threshold has led to decreased potency (Stone and Kranz, 2013).
Although in vitro evolution has been used to generate the majority of high affinity TCRs,
structure-guided computational design offers the potential for finer control over affinity and
specificity. Not only can interactions be manipulated in a way that more appropriately addresses
peptide specificity, affinity increments can in principle be more tightly controlled. Towards these
goals, structure-guided design has been used to modify a small number of TCRs (Haidar et al.,
2009; Malecek et al., 2014; Pierce et al., 2014; Zoete et al., 2013). Recently, we used structureguided design to engineer variants of the DMF5 TCR, which has been used clinically in
immunotherapy for melanoma and continues to serve as a model TCR for improving cancer
immunotherapy (Johnson et al., 2009). Building on an approach originally developed for the
well-studied A6 TCR (Haidar et al., 2009), we successfully engineered nanomolar affinity
variants of DMF5 with altered specificity, and found excellent agreement between prediction and
experiment for both structure and affinity (Pierce et al., 2014).
Here we addressed the generality of our TCR design efforts. We found that our approach
successfully used with DMF5 performed poorly with additional mutations and other, unrelated
TCRs. This may be attributable to the complexity of TCRs and their interfaces with pMHC, such
as varying binding geometries, sub-optimal packing and differing amounts of receptor and ligand
flexibility (Baker et al., 2012, Rossjohn et al., 2015). We therefore sought to develop a more
generalizable framework for TCR design. After assembling and modeling a large training set of
experimental binding data spanning multiple TCR–pMHC systems, we trained a candidate score
function which outperformed those used previously. Performance was further enhanced by
optimizing the scoring methodology and including information on receptor/ligand flexibility as
well as buried water. This allowed for successful design of new, affinity-enhancing mutations in
multiple TCRs, including an unrelated receptor not used in training. The new design framework
was also successful in recapitulating positive and negative effects of mutations to the MHC
protein as well as substitutions in the peptide, and captured emerging themes in TCR specificity
(Adams et al., 2016). Although there are avenues for improvement, these new developments
greatly extend the applicability of structure-guided design for the manipulation and screening of
TCR binding properties, and suggest ways for computational screening for peptide antigenicity.

Materials and Methods
Crystal structure processing and design parameters

For structural modeling, Rosetta with the Talaris2013 score function was used (Das and Baker,
2008; Kaufmann et al., 2010; Leaver-Fay et al., 2013; Moretti et al., 2013), using the PyRosetta
interface (Chaudhury et al., 2010). Native crystal structures were brought to local energy minima
through multiple cycles of backbone minimization and rotamer optimization with heavy atom
restraints (Bradley et al., 2005). Following structure minimization, the desired TCR, MHC, or
peptide mutation was computationally introduced followed by three independent Monte Carlo
based simulated annealing trajectories of the TCR CDR loops. This was performed using
Rosetta's LoopMover_Refine_CCD mover with 3 outer cycles and 10 inner cycles, using an
initial metropolis acceptance criteria of 2.2 that decreased linearly to 0.6 (Canutescu and
Dunbrack, 2003). The large number of resulting packing operations introduced some minor
variability when scoring the models. Therefore, the unweighted score terms for the three
trajectories were averaged and stored for point mutation energy calculations (Kellogg et al.,
2011). When screening TCR point mutations, TCR residue positions with a center of mass within
10 Å (DMF5 and B7) or 15 Å (DMF4) of a peptide heavy atom were selected for design. For
peptide screens, all positions other than the primary anchors of the MART126(27L)–35 peptide
underwent the design procedure. The design process sampled every amino acid (19 mutations
and the wild-type residue) at each specified position in triplicate. Wild-type complexes were
modeled and included in scoring to account for impacts of minimization and conformational
sampling. For double mutants, both mutations were introduced simultaneously followed by a
minimum of six independent minimization trajectories to account for additional structural
impacts.

Score function training
To develop a new score function for predicting changes in binding ΔΔG°, we considered Rosetta
full atom terms in addition to dynamically derived terms (bound and free order parameters and
RMS fluctuations). Multiple linear regression was performed in MATLAB 2015b using
measured ΔΔG° values. A stepwise elimination protocol was used to remove contextually
insignificant terms. A k-fold (k = 10) cross validation was performed with the data points and
significant predictor terms (Arlot and Celisse, 2010).

Modeling explicit water molecules and sarcosine
To model and score buried water molecules and the non-standard sarcosine, explicit TIP3P
waters and sarcosine parameters were enabled in Rosetta. Water molecules were placed at their
initial crystallographic coordinates followed by 100 high resolution docking trials to coordinate
the water molecule in the pocket of the interfaces. The water coordinates were then fixed in
position relative to the pMHC for TCR point mutation modeling.

Molecular dynamics simulations of bound and free structures
Molecular dynamics simulations were calculated utilizing the AMBER molecular dynamics suite
(Salomon-Ferrer et al., 2013) as previously described (Ayres et al., 2016). Results for the free
and bound A6 and DMF5 were taken from these simulations, with other simulations following
the same protocol. Briefly, coordinates for the complexes with the LC13, B7 and DMF4 TCRs
were obtained from PDB accession codes 1MI5, 1BD2 and 3QDM. Coordinates for the free

Tax11–19/HLA-A2 complex were from 1DUZ. For the LC13, B7 and DMF4 TCRs, coordinates
for the free TCRs were obtained by stripping away the pMHC. Prior to simulation, starting
systems were charge neutralized with explicit Na+ counterions and solvated with explicit SPC/E
water. Following this, systems were energy minimized and heated to 300 K with solute
restraints. Afterwards, solute restraints were gradually relaxed and followed with 2 ns of
simulation with no solute restraints for equilibration, after which 100 ns production trajectories
for all systems were calculated. Trajectories were calculated using GPU-accelerated code (Götz
et al., 2012; Salomon-Ferrer et al., 2013). Trajectory analysis including calculation of RMSF
values used the ccptraj from the AMBER suite (Roe and Cheatham, 2013). Order parameters
were calculated using isotropic reorientational eigenmode dynamic analysis using vectors
defined from the Cα to Cβ (or Cα to H for glycine) atoms (Prompers and Brüschweiler, 2002).
For double mutants, descriptors were averaged between the two positions for scoring purposes
(i.e. for mutant XY, the RMSF of position X is averaged with the position Y RMSF to give an
RMSF descriptor for XY).

Protein expression and purification
Expression and refolding of soluble constructs of the DMF5, B7 and DMF4 TCRs and HLA-A2
were performed as previously described (Davis-Harrison et al., 2005). Briefly, the TCR α and β
chains, the HLA-A2 heavy chain and β2-microglobulin (β2m) were generated in Escherichia coli
as inclusion bodies, which were isolated and denatured in 8 M urea. TCR α and β chains were
diluted in TCR refolding buffer (50 mM Tris (pH 8), 2 mM EDTA, 2.5 M urea, 9.6 mM
cysteamine, 5.5 mM cystamine, 0.2 mM PMSF) at a 1:1 ratio. HLA-A2 and β2m were diluted in
MHC refolding buffer (100 mM Tris (pH 8), 2 mM EDTA, 400 mM l-arginine, 6.3 mM
cysteamine, 3.7 mM cystamine, 0.2 mM PMSF) at a 1:1 ratio in the presence of excess peptide.
TCR and pMHC complexes were incubated for 24 h at 4°C. Afterward, complexes were desalted
by dialysis at 4°C and room temperature respectively, then purified by anion exchange followed
by size-exclusion chromatography. Refolded protein absorptions at 280 nm were measured
spectroscopically and concentrations determined with appropriate extinction coefficients.
Mutations in TCR α and β chains were generated by whole-plasmid mutagenesis and confirmed
by sequencing. Peptides were synthesized and purified commercially.

Surface plasmon resonance
Surface plasmon resonance experiments were performed with a Biacore 3000 instrument using
CM5 sensor chips as previously described (Davis-Harrison et al., 2005). In all experiments, TCR
was immobilized to the sensor chip via standard amine coupling and pMHC complex was
injected as analyte. Experiments were performed at 25°C in 20 mM HEPES (pH 7.4), 150 mM
NaCl, 0.005% Nonidet P-20. All experiments were steady-state experiments measuring RU vs.
concentration of injected analyte, and were performed with TCRs coupled onto the sensor chip at
400–2000 response units. Injected pMHC spanned a concentration range of 0.1–150 μM at flow
rates of 5 µl/min. Data were processed with BiaEvaluation 4.1 and fit using a 1:1 binding model
utilizing MATLAB 2015b.

Results
Application of earlier structure-guided design methods to the B7 TCR
Based on previous work with the A6 TCR (Haidar et al., 2009), we recently described a
modeling and scoring scheme to predict the structural and energetic effects of point mutations
within interfaces with the αβ TCR DMF5 (Pierce et al., 2014). Using this approach we identified
several affinity-enhancing mutations in DMF5 which when combined led to affinity
enhancements towards pMHC of up to 400-fold. To explore the generality of this approach, we
applied the same methodology to the B7 TCR (Ding et al., 1998), which binds the human T-cell
lymphoma virus Tax11–19 peptide presented by HLA-A2 with a similar affinity and orientation as
the A6 TCR (Fig. (Fig.1a).1a). The A6 and B7 TCRs also share the same germline-derived Vβ
chain, although crystallographic structures and biophysical studies of A6 and B7 with Tax11–
19/HLA-A2 showed structural and thermodynamic differences in binding (Davis-Harrison et al.,
2005). We modeled 740 point mutations in the B7-Tax11–19/HLA-A2 interface using Rosetta
(Das and Baker, 2008; Kaufmann et al., 2010) and the scheme described in Pierce et al. (2014).
As performed previously, effects were determined by scoring the complex, then separating the
components and separately scoring the TCR and pMHC in order to calculate a ‘binding score’
(Kortemme and Baker, 2002). Based on these scores, nine mutations were selected for predicted
enhancements to binding affinity and chosen for experimental testing.

Fig. 1 Mutations in the interface between the B7 TCR and Tax11-19/HLA-A2 are scored poorly
with the Rosetta interface and ZAFFI 1.1 functions. (a) Structural overview of the B7 TCR–
pMHC complex. (b) Score vs. experimental ΔΔG° for point mutations modeled with Rosetta and
scored with the Rosetta interface function. The best fit line and correlation coefficient is
indicated. (c) As with panel b, scored with the ZAFFI 1.1 function (Haidar et al., 2009; Pierce et
al., 2014).

We performed mutagenesis using soluble B7 gene constructs, expressed and purified the mutant
and wild-type proteins, and measured their binding affinities toward Tax11–19/HLA-A2 using
surface plasmon resonance (Table S1 and Fig. S1). Three of the mutations (S27αM, S50αY,
G99βY) led to moderately enhanced affinity towards Tax11–19/HLA-A2, although the remaining
six mutations weakened affinity or led to no detectable binding. Including four additional B7
mutations studied previously (Piepenbrink et al., 2013), the correlation between the predicted
and experimental change in binding energy was low with the Rosetta interface score function
(R = 0.21; Fig. Fig.1b).1b). Utilizing the ZAFFI score function first developed for the A6 TCR
and refined with the DMF5 TCR (Haidar et al., 2009; Pierce et al., 2014) led to an improved but

still weak correlation (R = 0.47; Fig. Fig.1c).1c). Thus, the TCR design approach developed for
the A6 TCR and later applied to DMF5 performs poorly with the B7 TCR.

Collection of new data to train a score function for HLA-A2-restricted TCRs
In light of the low correlations between prediction and experiment with the B7 TCR, we aimed
to develop a more generalizable framework for modeling and predicting point mutations across
multiple TCR–pMHC interfaces. We collected 96 independent ΔΔG° values resulting from
single amino acid mutations from four TCR–pMHC interfaces (A6-Tax11–19/HLA-A2; B7-Tax11–
19/HLA-A2; DMF5-MART127–35/HLA-A2; and DMF5-MART126(27L)–35/HLA-A2). This data
originated from our previously published structure-guided design efforts with the A6 and DMF5
TCRs (Haidar et al., 2009; Pierce et al., 2014) as well as our recent double mutant cycle
deconstruction of the A6 interface (Piepenbrink et al., 2013). We also included the additional
data with B7 described above, and performed new binding measurements in the DMF5MART126(27L)–35/HLA-A2 interface (Table S1 and Fig. S1). We restricted the dataset to high
quality measurements with low experimental error (< 0.5 kcal/mol).
The point mutations in our dataset covered a broad range of mutation types as described in Table
S2. The ΔΔG° values ranged from −1.8 to 2.8 kcal/mol and were approximately normal in
distribution (Fig. (Fig.2a).2a). The median ΔΔG° value of the selected dataset was 0.5 kcal/mol
with a standard deviation of 1.1 kcal/mol. When comparing the 29 mutations that improved
binding, it became evident the majority of affinity-enhancing mutations resulted from
replacement of small or polar residues with large hydrophobic or amphipathic residues (Fig.
(Fig.22b).

Fig. 2 Experimental ΔΔG° values of TCR point mutations are normal in distribution and affinityenhancing mutations are predominantly hydrophobic or amphipathic. (a) The 96 point mutations
collected in different TCR–pMHC interfaces were approximately normal in distribution with a

median ΔΔG° value of 0.5 kcal/mol and a standard deviation of 1.1 kcal/mol. (b) Sequence logos
of the 29 mutations that improved binding (ΔΔG° < 0).

Development of a generalized TCR–pMHC scoring function
We next developed computational structural models of all 96 point mutations for training
generalized TCR prediction models. We extended our strategy by adapting techniques for
modeling the effects of interface mutations shown to be successful in recent community-wide
assessments. Mutations were modeled with the standard Talaris2013 score function allowing for
off-rotamer sampling and limited backbone flexibility in the CDR loops (Leaver-Fay et al.,
2013; Moretti et al., 2013). Additionally, side chains of residues within a 10 Å sphere of any
CDR loop residue were repacked in response to each mutation and resulting CDR loop
movements. Each point mutation was modeled in triplicate and scores averaged for further
analysis. Analysis of the mutation models identified one with an anomalously high repulsive
clash score and another where a residue was forced into an unusual high energy rotamer. Both of
these mutations were excluded from further training and comparisons, leaving a dataset of 94
point mutations and their structural models.
To develop a generalizable TCR scoring function, we considered 16 full-atom Rosetta terms
commonly used for protein design and structure prediction (Leaver-Fay et al., 2013; Moretti et
al., 2013). Using the Rosetta terms as predictor variables and experimental binding energies of
the dataset described above as the response variable, we used multi-linear regression to
parameterize a starting score function for estimating the effect of the various point mutations on
ΔΔG°. The most significant contributors to the model (P < 0.05) described van der Waals
attractive forces and solvation effects. However, the correlation between binding score and
ΔΔG° remained low (R = 0.43; Fig. Fig.3a).3a). Thus we did not explore removing insignificant
features at this stage in favor of obtaining a more robust prediction model.

Fig. 3 Relative TCR–pMHC complex scores correlate better with affinity than binding scores.
(a) Scores vs. experimental ∆∆G° for modeled point mutations. Scores were determined by
scoring each complex and two free proteins (i.e. binding score = scorecomplex − (scoreTCR +
scorepMHC)). The wild-type ‘binding score’ was then subtracted from each mutant binding score.
After parameterization of Rosetta structural terms, relative binding scores were plotted vs.
experimental ΔΔG°. (b) As with panel a, but scores determined and parameterized by scoring
only the wild-type and each mutant complex, yielding ‘complex scores’ as described in the text.

Ideally, binding energy calculations would utilize structural information for both the free and
bound molecules (Kortemme and Baker, 2002; Vreven et al., 2012). However, structures of free
TCRs and pMHCs can vary between free and bound states (Armstrong et al., 2008), and the
large surface areas of receptor and ligand binding sites possess significant conformational
degrees of freedom. We thus focused only on relative effects by scoring only TCR–pMHC
complexes, rather than scoring the complex and the two free proteins as described above. We
refer to the difference in scores between wild type and mutant complexes as ‘complex scores’.
This approach comes with a limitation in that complex scores do not account for energies in the
free TCR associated with making the mutation (i.e. the ΔG° for TCR WT ↔ TCR mutant).
Ideally these would be subtracted when examining the impact of a mutation on binding. There
are two potentially significant consequences to this. First, an improved complex score could arise
solely due to improved contacts within the TCR (i.e better TCR stability). We minimized the
impact of this by focusing on sites that are in proximity to the ligand and thus more likely to
influence binding. Second, any effects on binding stemming from conformational changes in the
free TCR will be ignored.
Using the same 16 full-atom Rosetta terms, a multi-linear regression of complex scores vs. ΔΔG°
yielded an improved function (R = 0.66 for complex scores, vs. R = 0.43 for binding scores; Fig.
Fig.3b).3b). Despite the theoretical limitations noted above, complex scores are therefore more
applicable for our framework and were used for all further calculations. The improvement using
complex scores may reveal underlying limitations in the energy function terms and/or limitations
in recapitulating conformational differences between free and bound TCRs as noted above,
leading to inaccuracies when ‘binding scores’ are computed. The inherently weak affinities and
correspondingly poor quality of TCR–pMHC interfaces (compared, e.g. to high affinity
antibody-antigen interfaces) could also contribute to why complex scores outperform binding
scores.

Refinement of the regression model to include flexibility and validation of terms
Although utilization of complex scores improved the correlation between prediction and
experiment, we sought to identify additional predictors of TCR binding affinity that might
further improve performance. One of the differences between TCRs is their degree of binding
loop flexibility, particularly for the hypervariable CDR3α and CDR3β loops (Scott et al., 2011).
Although various methods for conformational sampling such as stochastic loop perturbations or
generation of structural ensembles exist (Feixas et al., 2014; Sinko et al., 2013; Tuffery and
Derreumaux, 2012), these are computationally expensive. To more simply address the impacts of
TCR loop flexibility, we considered descriptors from molecular dynamics (MD) simulations of
the free and bound TCRs. We recently described a comprehensive MD study of the free and
bound A6 and DMF5 TCRs (Ayres et al., 2016) using an experimentally benchmarked
simulation methodology (Scott et al., 2011, Scott et al., 2012). We performed similar simulations
on the free and bound B7 TCR. From these simulations root mean square (RMS) fluctuations for
each α carbon were determined along with Cα-Cβ (Cα-H for glycine) and Cα-C order parameters
to quantify nanosecond timescale backbone flexibility (Fig. S2). Due to the time that would be
required to simulate dozens or hundreds of mutations, only the wild-type TCRs and their
complexes were simulated. Fluctuation values and order parameters were then treated as
‘positional modifiers’ for each amino acid position, biasing positions for design based on their

relative flexibility in the wild-type free and bound structures. Although necessary for throughput,
this approach makes the limiting assumption that any given mutation does not impact backbone
flexibility on the nanosecond timescale.
To determine if inclusion of RMS fluctuations and/or order parameters could lead to an
improved scoring function, we included these six terms along with the 16 full-atom Rosetta
terms in a multi-linear regression of complex scores vs. ΔΔG°, coupled with a stepwise
elimination protocol (Hocking, 1976). This fit identified six significant (P < 0.05) features: four
structural terms (van der Waals attractive and repulsive forces, solvation energies and sidechain
hydrogen bonding) and two flexibility terms (RMS fluctuations for α carbons of the free and
bound structures). A structural term weighting Ramachandran angle propensities was borderline
significant (P = 0.11), but was retained to help identify and exclude structural models with
residues forced into unrealistic conformations.
The regression models estimated the weights of the RMS fluctuation features to be negative,
suggesting flexible positions are more favorable to target for design (although mobility in the
complex was weighted more heavily as discussed below). To critically examine the significance
of this determination, models with and without the fluctuation terms in addition to the five
Rosetta terms were generated and compared. Akaike information criterion (AIC) (Akaike, 1998)
found the incorporation of features describing flexibility resulted in a 99.8% likelihood of a
superior prediction model. Bayesian information criterion (BIC) (Kass and Raftery, 1995) more
strongly penalized additional terms, yet also indicated that inclusion of the fluctuation terms
improved the regression model beyond random chance (Table (TableII).

Table I.
Inclusion of RMS fluctuations improves the score function regression model
Criteria
R
P-value
AIC
BIC

RMSF excluded
0.63
7.9 × 10−9
239.2
254.4

RMSF included
0.71
9.0 × 10−11
226.8
246.2

Finally, a k-fold cross validation (k = 10) (Arlot and Celisse, 2010) was used to validate and
estimate overall predictive performance. From this analysis, the RMS error (reflecting the
difference between experimental and predicted ΔΔG° values) was estimated as 0.81 kcal/mol,
with an impressive correlation of 0.71 (Fig. (Fig.4a;4a; note this correlation includes accounting
for structural water as described below). For comparison, our previous approach with the Rosetta
interface score function yielded a correlation of only 0.16 (Fig. (Fig.4b),4b), and a recent
analysis of protein design approaches estimated an average error of 1.2 kcal/mol for protein–
protein interactions (Potapov et al., 2009). The terms and weights for the final regression model,
termed the TR3 score function, are shown in Table TableIIII.

Fig. 4 The TR3 score function outperforms our previous TCR design methodology. (a) Complex
score vs. experimental ΔΔG° for 94 point mutations modeled with Rosetta and scored with the
TR3 function. The best fit line, 95% confidence interval, and correlation coefficient is indicated.
(b) Performance of our previous methodology applied to the same data. An off-scale prediction
score of 26 (DMF5 G28αL) is denoted by a black arrow and the best fit line and correlation are
indicated.

Table II.
Terms and their statistics in the TR3 score function
Term
Weight
Intercept
2.29
Fa_atr
0.21
Fa_rep
0.05
Fa_sol
0.18
Hbond_sc
0.34
Rama
0.12
RMSF_bound
−0.82
RMSF_free
−0.36
Estimated error: 0.81 kcal/molc

Errora
0.35
0.03
0.01
0.08
0.09
0.05
0.30
0.10

P-valueb
<0.001
<0.001
0.005
<0.001
0.008
0.119
0.049
0.003

a

Determined as 1.96 standard deviations of k-fold cross-validation weights.
P-value for the F statistic of the hypotheses test that the corresponding coefficient is equal to
zero.
c
Average test RMS error from k-fold cross validation.
b

Accounting for energetically significant structural water improves predictions
Rosetta utilizes an implicit solvation model to estimate solvation energies associated with bulk
water (Lazaridis and Karplus, 1999). However, TCR–pMHC interfaces are large and buried
water molecules are often observed crystallographically. In some instances these structural
waters play key roles in the interface that would not be captured with an implicit solvation model
(Jiang et al., 2005). Indeed, many predicted mutations which filled the void of an interfacial
water molecule in the interface with the DMF5 TCR resulted in a falsely favorable score. For
example, Ser99 in the DMF5 β chain contacts the peptide, but is also involved in a complex
water-mediated hydrogen bond network linking the peptide to the TCR (Fig. (Fig.5a).5a). The
predicted impacts of mutations at this position did not correlate well with experiment (Fig.
(Fig.5b),5b), consistent with a determination that this water molecule is structurally and
energetically significant. To directly account for it, the buried water in the DMF5 interface was
docked into its corresponding pocket and treated explicitly in modeling and scoring. This
improved the agreement between prediction and experiment for Ser99β point mutations without
altering the predictions for distant residues (Fig. (Fig.5c).5c). Further design efforts incorporated
this technique when buried water molecules were observed crystallographically in the interface
between peptide and TCR (i.e. the DMF4 and LC13 TCRs as described later).

Fig. 5 Accounting for buried structural water improves predictions. (a) A buried water molecule
observed crystallographically in the DMF5-MART126(27L)-35/HLA-A2 interface forms multiple
electrostatic interactions between the TCR and peptide. The sidechain of Ser99 of the DMF5 β
chain is indicated. (b) The correlation between prediction and experiment for models of DMF5
point mutants scored with TR3 is 0.63 when the buried water molecule is ignored. Five
mutations at position 99β are indicated and are responsible for the low correlations. (c) The
correlation between prediction and experiment for DMF5 point mutants improves to 0.80 when
the buried water molecule is treated explicitly. The predicted effects of the five mutations at
position 99β agree better with experiment as shown.

Validation with new TCR mutations and combinations to further modulate
affinity
We next collected additional data to assess the performance of our new framework on mutations
not used in training. We screened for new mutations in the interfaces with the DMF5 and B7
TCRs (DMF5-MART126(27L)–35/HLA-A2 and B7-Tax11–19/HLA-A2). To emphasize peptide
specificity, only positions with a center of mass within 10 Å of a peptide heavy atom were
selected for design. A total of 18 sites in both DMF5 and B7 were modeled and scored with all
20 amino acids (684 point mutations in total and 36 wild-type controls). As expected, most
mutations were predicted to have deleterious effects on binding. However, several mutations
were predicted to enhance affinity, most at sites where mutations have previously been shown to
favorably impact binding (Table S1). The two predicted to be most favorable (G99βW for B7;
D26αF for DMF5) were both generated, and the impact on binding assessed experimentally.
Both mutations improved binding as predicted. The ΔΔG° for G99βW in B7 was −0.5 kcal/mol;
for D26αF in DMF5 it was −0.4 kcal/mol. The value for D26αF was less than observed
previously with tyrosine or tryptophan at this position (−1.8 and −1.6 kcal/mol, respectively),
suggesting that the amphipathic character of tyrosine and tryptophan may be advantageous for
enhancing TCR affinity as discussed below.
Our previous designs for the A6 and DMF5 TCRs combined multiple mutations to generate
molecules which bound in the nanomolar range (Haidar et al., 2009; Pierce et al., 2014). The
approximate additive effects of mutations in both interfaces were captured by our new
framework with the TR3 score function after averaging the RMSF positional values of each of
the mutations. To ask if our new framework also allowed for this in another TCR, we combined
the S27αM and G99βY mutations in the B7 receptor, which together improved the B7 affinity
for Tax11–19/HLA-A2 7-fold, from 1.5 μM to 220 nM (Fig. (Fig.6).6). These mutations are ~27 Å
apart, and were correctly predicted to be additive when combined (ΔΔG° = −1.2 kcal/mol,
complex score = −0.77).

Fig. 6 Combining two computationally designed B7 mutations yields nanomolar binding affinity.
(a) Combining the S27αM and G99βY mutations in the B7 TCR improves binding to Tax1119/HLA-A2 7-fold, from 1.5 µM to 220 nM. (b) The sites of the S27αM and G99βY mutations in
the B7 TCR are separated by ~27 Å and are predicted to improve affinity independently through
improved van der Waals interactions with the pMHC.

To investigate broader applicability, mutations in another TCR not used in training were
modeled and scored. The DMF4 TCR also recognizes MART1 antigens presented by HLA-A2,
but utilizes different α and β chains than DMF5, A6 and B7 (Borbulevych et al., 2011; Johnson
et al., 2009). As performed with the A6, B7 and DMF5 TCRs, MD simulations of the free wildtype DMF4 TCR and its complex with MART126(27L)–35/HLA-A2 were performed and used
along with Rosetta to simulate 960 structures (19 mutations at 48 sites, and 48 wild-type
controls) in the DMF4-MART126(27L)−35/HLA-A2 interface. Several mutations in the α chain
were favorably ranked based on their ability to fill an interfacial void near the N-terminus of the
peptide. Three of these mutations were selected for experimental investigation (S26αW, N29αW
and T92αW). Although the N29αW mutation was of particular interest as it provided another
opportunity to investigate a structural water, this mutant could not be folded from inclusion
bodies. This left two mutations for experimental testing. As predicted, both of these enhanced
DMF4 binding affinity, with ΔΔG° values of −0.4 and −0.9 kcal/mol (Table S1). These
mutations were also predicted and found to be additive when combined: together the S26αW and
T92αW mutations improved the affinity of the DMF4 TCR 10-fold, from 60 to 6 µM (ΔΔG° of
−1.4 kcal/mol).
Overall, when applied to data outside of our training set, our new modeling and scoring
procedure recapitulated the effects of multiple mutations in the B7, DMF5 and DMF4 TCRs and
permitted the identification of new affinity-enhancing mutations in all three receptors. The RMS
error between predicted and experimentally determined impacts on binding was 1.5 kcal/mol,
higher than observed with training and cross-validation but still lower than observed with our
previous methodology (Fig. (Fig.7a,7a, black points).

Fig. 7 Performance of our improved framework on new TCR mutations, HLA-A2 mutations and
peptide variations. (a) All point mutation data examined in evaluating our new approach,
including TCR, peptide and HLA-A2 data, plotted together, excluding data used in training. The
overall correlation between prediction and experiment is 0.86. (b) The predicted effects of
MART126(27L)-35 peptide substitutions on the binding of DMF5 to MART126(27L)–35/HLA-A2
indicate amino acids that are more tolerating of or more sensitive to substitutions. Position 6 near
the center of the peptide is particularly sensitive. Each segment of the plot shows the complex
scores for all 20 amino acids substituted at the indicated position. Solid lines and numbers in
each segment show the average scores for all 20 amino acids at that position. (c) Performance is
more limited on a system involving a more diverse, non-HLA-A2 restricted TCR. The impact of
mutations in the LC13 TCR with FLR/HLA-B8 are predicted with a correlation coefficient of
0.60 (ΔΔG° values of mutations with no detectable binding were reported previously as 1.6
kcal/mol) (Borg et al., 2005).

Including HLA-A2 mutations in validation
αβ TCRs show MHC restriction, i.e. they recognize peptides only when presented by MHC
proteins (Zinkernagel and Doherty, 1974). Many studies have examined the effects of mutations
in the α helices of MHC binding groove as a means to determine energetically significant
positions that might guide restriction, including a recent comprehensive analysis of the binding
of A6 TCR to the Tax11–19/HLA-A2 complex. Of nine published mutations, eight weakened
affinity and one enhanced affinity (Piepenbrink et al., 2013). To recapitulate this data in silico,
we modeled the impact of mutations in HLA-A2 on the binding of A6 to Tax11–19/HLA-A2,
incorporating free and bound flexibility through MD simulations as described above. The effects
of these mutations were well captured, with RMS error between prediction and experiment of 1.0
kcal/mol (Fig. (Fig.7a,7a, green points). Thus our new framework is applicable not only to
TCRs, but can predict the energetics associated with mutations in the HLA-A2 side of the
interface as well.

Computational scanning of peptide variants
TCRs are broadly cross-reactive and recognize a multitude of antigenic peptides, a requirement
of the fixed size of the T-cell repertoire (Mason, 1998). Additionally, altering TCR binding by
changing peptide sequence is another approach for modulating TCR binding and immune
responses (McMahan and Slansky, 2007; Piepenbrink et al., 2009). Quantitative data for how
eight substitutions in the Tax11–19 peptide impact the binding of the A6 TCR is available (DavisHarrison et al., 2007; Piepenbrink et al., 2013), and we collected new alanine scanning data for
recognition of four more Tax11–19 variants by B7 (Table S1). As with the HLA-A2 mutations
above, we used our new modeling and scoring approach to assess how these peptide variants
impact recognition by A6 and B7. The impacts on binding ΔΔG° were recapitulated well, with
an RMS error of 0.9 kcal/mol (Fig. (Fig.7a,7a, yellow points).
To further demonstrate the utility of our approach for assessing peptide variations, residues in the
MART126(27L)–35 peptide were computationally varied to cover all 20 amino acids, and, after
completing a MD simulation of the MART126(27L)–35/HLA-A2 complex, scored for impact on
DMF5 binding. All peptide substitutions were predicted to be unfavorable, although mutations at
the P3 and P6 positions were predicted to have the most dramatic impacts (Fig. (Fig.7b).7b).
This outcome is consistent with recent findings on TCR specificity, which suggest the existence
of peptide ‘hotspots’ of reduced structural and chemical diversity, outside of which greater
variation is permitted (Adams et al., 2016).
Next, eight MART126(27L)–35 peptide variants with a broad range of complex scores were selected
for experimental testing with DMF5 (Table S1). We also examined a peptide with a non-standard
sarcosine (N-methyl glycine) substituted for Gly6 of the peptide to help test the implications of
treating structured water explicitly in the DMF5 interface as discussed above and shown in Fig.
Fig.5.5. Overall, there was a good correlation between ΔΔG° and binding score for the nine
MART126(27L)–35 peptide variants explored experimentally, with experiment and prediction
differing with an RMS error of 0.9 kcal/mol (Fig. (Fig.7a,7a, blue points). The experiments with

the sarcosine-modified peptide led to improved binding as predicted, leading to a 3-fold affinity
enhancement in affinity (ΔΔG° of −0.6 kcal/mol). The affinity enhancement is attributable to the
increased van der Waals interactions to Thr102 of the TCR while maintaining the solvated state
of polar atoms in the surrounding pocket.

Overall performance and exploration of an even more diverse, non-HLA-A2
interface
To explore the overall performance of our new approach, we examined the new TCR mutations,
HLA-A2 mutations and peptide variants described above together as one large test set. These
amounted to 40 independent ΔΔG° measurements distinct from the training set from five
different TCR–pMHC interfaces. We also included the double mutants in the DMF5, B7 and A6
TCRs. Altogether, performance was excellent, with predicted and experimental impacts on
binding agreeing with an impressive correlation coefficient of 0.86 and a RMS error of 1.1
kcal/mol, spanning a large range of ~7 kcal/mol in binding free energy (Fig. (Fig.7a,7a, all
points). Complex scores again showed improved performance over binding scores, as scoring the
40 test set mutations using binding scores yielded a weaker correlation coefficient (R = 0.66) and
larger RMS error (2.8 kcal/mol) (Fig. S3).
The systems used in development and testing all involved the class I MHC protein HLA-A2. To
explore how our new framework performed when additional diversity was included, we used it
to assess the impact of mutations between the interface of the LC13 TCR and the class I MHC
protein HLA-B:08:01 (HLA-B8) presenting the FLR peptide (sequence FLRGRAYGL). The
structure of the LC13-FLR/HLA-B8 complex has been determined, as have ΔΔG° values for 39
alanine or glycine mutations in the various LC13 CDR loops (Borg et al., 2005). After
completing MD simulations of LC13 and its complex, we applied our approach to this dataset,
recapitulating the effects of these mutations with an overall correlation of 0.60 and an RMS error
of 1.0 kcal/mol (Fig. (Fig.7c).7c). While errors are still within the range obtained with our
previous methodology (Pierce et al., 2014), the correlation is weaker than what we achieved with
HLA-A2-restricted systems.
There are at least two possible reasons for the weaker performance with the LC13 TCR. First,
many of the 39 mutations in the LC13 interface result in very weak or no detectable binding,
with ΔΔG° values reported simply as above an upper limit of 1.6 kcal/mol (corresponding to a
15-fold weakening of affinity). The limited accuracy of these measurements will affect the
correlation between prediction and experiment. As evidence of this, binary metrics demonstrated
good predictive performance when separating affinity increasing mutations from affinity
decreasing mutations (ROC AUC = 0.84; Fig. S4). Second, our reliance on HLA-A2-restricted
systems in parameterization of the new TR3 score function could result in an inherent bias.
HLA-A2 and HLA-B8 differ by 42 amino acids, 32 of which are in the peptide binding domain
(Robinson et al., 2011). In addition to different energetic contributions, these differences could
alter the structural and dynamic responses to mutations in ways that are poorly captured by our
framework.

Discussion
TCRs have emerged as a new class of immunological therapeutics, most prominently for cancer,
where they are the key components of new cellular immunotherapies as well as soluble biologics
(Oates and Jakobsen, 2013; Restifo et al., 2012). There is significant interest in enhancing TCR
affinity to improve antigen sensitivity, and accordingly, numerous high affinity TCRs have been
generated. Although T-cell potency has been shown to improve with affinity, questions remain
about the existence of optimal affinity windows or thresholds and the merits of large vs.
incremental improvements in binding affinity (Stone and Kranz, 2013). Additionally, following
adverse events in clinical trials (Morgan et al., 2013; Parkhurst et al., 2011), there is a growing
recognition of the importance of evaluating and controlling specificity in affinity-enhanced or
otherwise modified TCRs.
In principle, structure-guided computational design offers the potential for fine manipulation of
TCR binding properties. Structure-guided design has been used to generate a small number of
high affinity TCRs, as well as manipulate binding specificity (Haidar et al., 2009; Malecek et al.,
2014; Pierce et al., 2014; Zoete et al., 2013). However, although the TCR–pMHC structural
database has grown significantly in recent years, wide-scale application of structure-guided TCR
design is hindered by several complexities. These include the complex architecture of the TCR–
pMHC interface (Baker et al., 2012; Rossjohn et al., 2015), as well as the varying degrees of
diversity and molecular flexibility in both receptor and ligand (Borbulevych et al., 2009;
Insaidoo et al., 2011; Scott et al., 2011). We demonstrated the limited applicability of current
TCR design approaches here by showing that our prior approach used to successfully engineer
the clinically relevant DMF5 TCR performed poorly when applied to the unrelated B7 TCR.
To generate an improved framework for structure-guided TCR design, we assembled a large
database of mutations from four TCR–pMHC interfaces and used this in developing a new,
‘general purpose’ approach to TCR design, including a novel score function. Similar to other
score functions trained to predict binding affinity (Kortemme and Baker, 2002), the results
heavily weighted van der Waals attractive forces and solvation and dampened repulsive terms.
We also accounted for molecular flexibility via a novel cost-effective approach. For data in the
training set we were able to achieve a correlation between predicted effect on binding and
experimental ΔΔG° of 0.71. When applied to new data from multiple TCRs, HLA-A2 and
peptides, we obtained an impressive correlation of 0.86 and low RMS error of 1.1 kcal/mol,
which is near the expected upper limit due to error in experimental data (Potapov et al., 2009).
As with other studies, the slope of predicted vs. experimental ΔΔG° was <1, indicating that
impacts on binding affinity are typically under-estimated, giving some indications of ways to
improve. The potential for further improvements is also found with the better performance
observed with complex vs. binding scores, despite the theoretical limitations associated with
complex scores.
Accounting for flexibility is an important aspect of our improved framework, as varying degrees
of CDR loop, MHC and peptide flexibility is a characteristic feature of TCRs and pMHC
complexes (Borbulevych et al., 2009; Insaidoo et al., 2011; Scott et al., 2011). As with other
efforts in protein design, we relied on MD simulations to incorporate flexibility. However, as
opposed to simulating structures to identify alternate configurations or generate structural

ensembles (Feixas et al., 2014; Sinko et al., 2013; Tuffery and Derreumaux, 2012), we added
‘positional modifiers’ that report on amino-acid level motional properties as terms in the score
function. We chose this approach as it greatly simplifies the treatment of flexibility, requiring
only single MD trajectories for the free wild-type TCR and the TCR–pMHC complex. Of the
properties considered, Cα RMS fluctuations were most significant and were incorporated into the
final function. The weights for these terms were negative, indicating that more flexible positions
are more favorable for design. There is some anecdotal evidence to support this: in the A6 TCR,
the hypervariable CDR3β loop is by far the most mobile, and multiple mutations within this loop
improve A6 binding (Haidar et al., 2014; Li et al., 2005; Scott et al., 2011). This could reflect a
form of the ‘fly-casting’ effect, in which mobile sites in a receptor are more adept at finding
compatible partner sites in a ligand (Shoemaker et al., 2000). Interestingly, the flexibility
weights were larger for residues in the bound state. While residual mobility in TCR–pMHC
interfaces has been observed and this term could be accounting for this (Hawse et al., 2014;
Reboul et al., 2012), it is also possible that in the complex this term helps overcome limited
conformational sampling in modeling. Further work is needed to explore this, along with
whether using longer or additional MD simulations can yield further improvements, at the
expense of throughput.
Solvent considerations can be important in structure-guided design, as buried water molecules
can play critical roles in protein binding (Janin, 1999; Rodier et al., 2005). As seen in other
systems (de Graaf et al., 2005), we demonstrate that explicitly modeling water in TCR interfaces
can improve predictions. This was most useful for the DMF5 TCR, although buried waters were
incorporated when modeling the DMF4 and LC13 interfaces as well (chosen in these cases
because they were buried in the interface and participated in multiple hydrogen bonds with the
TCR, peptide or MHC). Because we relied on crystallographically observed water, there is a
corresponding demand on the resolution and quality of the original crystal structure. As TCR–
pMHC interfaces may be poorly packed and crystallographic resolutions low, incorporation of
approaches to predict the location of water molecules not observed crystallographically could
lead to further improvements (Bui et al., 2007; Jiang et al., 2005).
Our improved framework for TCR design permitted the identification of new affinity-enhancing
mutations in multiple interfaces, including the DMF4 TCR which was not used in training and
uses different Vα and Vβ genes than those in the training set (Borbulevych et al., 2011; Johnson
et al., 2009). The enhancements to affinity are relatively modest, but as noted above fine control
may be most desirable when manipulating TCR affinity. Additionally, when combined these
mutations can yield larger improvements, as shown for the B7, A6, DMF4 and DMF5 TCRs.
Our approach also accounted for the relative effects of alanine and glycine mutations in another
TCR, LC13, although the poorer performance with this receptor suggests that application to class
I MHC proteins other than HLA-A2 (such as the HLA-B8 allele recognized by LC13) could
require additional training outside of HLA-A2 systems to improve generality. By extension, we
can expect that application towards other MHC proteins, particularly class II or nonclassical
MHC proteins, will also require further effort.
Mutations which enhanced affinity tended to be (although were not exclusively) those that
replaced small polar or charged residues with large hydrophobic or amphipathic amino acids.
The significance of this is unclear; this was seen in our training data as well as new mutations.

Increasing buried hydrophobic surface area is a well-known strategy for enhancing binding, and
the rigid, bulky and amphipathic nature of tyrosine and tryptophan provide structural and
chemical utility (Koide and Sidhu, 2009). Highly antigenic peptides have a tendency to be
enriched in hydrophobic amino acids in TCR contact sites (Chowell et al., 2015), potentially
indicating that such amino acids are indeed optimal for enhancing TCR affinity.
What do these results indicate about introducing charged or polar amino acids? While
electrostatic interactions can contribute to specificity, their contributions to affinity can vary due
to high desolvation penalties (Bosshard et al., 2004; Hendsch and Tidor, 1994). Additionally,
electrostatic interactions have strict geometrical dependences. Due to these complexities, protein
design algorithms are recognized to have limited success modeling electrostatics (Fleishman et
al., 2011; Procko et al., 2013; Stranges and Kuhlman, 2013). Thus introduction of charged or
polar interactions may be unintentionally disfavored during design. Overcoming this potential
limitation is important, as an over-reliance on select amino acids limits applicability. Further,
accurately accounting for electrostatic effects could provide another means to selectively
engineer TCR specificity, irrespective of their impacts on binding affinity (Blevins et al., 2016;
Stadinski et al., 2016).
The availability of polar/charged mutations that improve TCR binding will be helpful in further
assessing and improving our design framework. Molecular evolution experiments can provide
such data, although because multiple mutations are often found in affinity-matured molecules,
identifying the impact of individual mutations can be difficult. Perhaps a more promising source
for such data could be deep mutational scanning experiments, which sample the effects of every
amino acid at multiple positions in one experiment (Fowler and Fields, 2014; Whitehead et al.,
2012). Our recent deep mutational scanning experiments with the A6 and variant TCRs provide
several promising examples of polar/charged mutations that appear to favorably impact binding
(Harris et al., 2016), and careful analysis of these will be helpful.
Lastly, our approach was also able to account for the effects of mutations in the HLA-A2 protein
as well as peptide substitutions. This raises the possibility of using computational design not only
for engineering TCRs to modulate their binding properties, but also ligands with enhanced
affinity for select TCRs. Such an approach has been proposed as a novel means for peptide-based
vaccine design (McMahan and Slansky, 2007; Piepenbrink et al., 2009), and could be useful in
the development of new T-cell detection or imaging reagents. Additionally, the capacity to
accurately score peptide variants could allow for computationally assessing the cross-reactivity
of TCRs or the reactivities of peptide sets. This could prove useful for predicting and controlling
off target toxicity for TCRs used clinically or identifying reactive self-antigens in autoimmunity,
transplantation or vaccination.
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Figure S1. Representative TCR-pMHC SPR binding data for experiments shown in Table S1.
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Figure S2. Root mean square fluctuations from MD simulations of free and bound TCRs and pMHC complexes.
For TCRs, shaded boxes indicate the locations and values of the six CDR loops. Data for the A6 and B7 TCRs
is from Ayres et al., 2016.
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Figure S3. Performance of our improved framework on new TCR mutations, HLA-A2 mutations, and peptide variations
when evaluated using binding rather than complex scores. All point mutation data examined in evaluating our new
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Table S1. New binding data for TCR mutations and peptide substitutions in the B7, DMF5, and DMF4
TCR-pMHC interfaces

a

TCR

Peptidea

B7
B7
B7
B7
B7
B7
B7
B7
B7
B7
B7
B7
B7
B7
B7
DMF5
DMF5
DMF5
DMF5
DMF5
DMF5
DMF5
DMF5
DMF5
DMF5
DMF5
DMF5
DMF5
DMF5
DMF5
DMF5
DMF5
DMF5
DMF4
DMF4

Tax
Tax
Tax
Tax
Tax
Tax
Tax
Tax
Tax
Tax
Tax
Tax
Tax
Tax
Tax
ELA
ELA
ELA
ELA
ELA
ELA
ELA
ELA
ELA
ELA
ELA
ELA
ELA
ELA
ELA
ELA
ELA
ELA
ELA
ELA

TCR mutation or
peptide substitution
S27αM
D30αQ
S50αY
M93αE
M93αQ
Q102αW
P97βW
G98βF
G99βY
G99βW
S27αM/G99βY
pF3A
pY5A
pY5F
pY8A
D26αF
R27αF
K96αW
T54αI
S99βF
S99βH
S99βI
S99βL
S99βT
pE1A
pE1D
pE1F
pE1Q
pI5E
pG6-Sarc
pL8A
pT9A
pT9W
S26αW
T92αW

ΔΔG° (kcal/mol)

Error (kcal/mol)

-0.43
>2
-0.73
>2
1.94
0.56
>2
0.82
-0.39
-0.47
-1.15
2.7
3.28
0.55
2.76
-0.43
-0.3
-0.65
0.33
>2
1.48
1.36
2.27
0.4
0.06
1.3
2.26
1.0
3.07
-0.58
>3
1.6
>3
-0.63
-0.38

0.08
NDb
0.09
ND
0.1
0.14
ND
0.09
0.11
0.08
0.1
0.02
0.11
0.04
0.07
0.1
0.13
0.12
0.12
ND
0.11
0.09
0.03
0.13
0.19
0.26
0.06
0.03
0.18
0.07
ND
0.03
ND
0.04
0.06

Tax = HTLV Tax11-19 (LLFGYPVYV); ELA = MART-126(27L)-35 (ELAGIGILTV)
ND = not determined

b

Table S2. Descriptive breakdown of training set data
Total mutations in training set
Polar/charged WT residues
Polar/charged mutant residues
Mutations with polar/charged WT & mutant residues
Large hydrophobic/aromatic WT residues1
Large hydrophobic/aromatic mutant residue
Mutations with large hydrophobic/aromatic WT & mutant residues
Alanine mutations2
Alanine mutations with large/hydrophobic WT residues
1
Large hydrophobic/aromatic residues defined as Y/W/L/I/F/M
2
Excluding mutations with glycine WT residues

94
56
24
11
14
41
7
22
5

(60%)
(26%)
(12%)
(16%)
(44%)
(7%)
(23%)
(5%)

